Computed tomography imaging findings in erythrodermic psoriasis treated with infliximab: A case report

Kurokawa, Ryo; Hagiwara, Akifumi; Niijima, Yasuko; Kojima, Kaoru

doi:10.1016/j.radcr.2018.02.005

Cited by 5 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 serious AE (erythema multiforme) 3 AE (erythema multiforme, psoriasis, latent tuberculosis) led to treatment discontinuation. Infliximab Case Series Takahashi et al 23 7 Pt 1: 39/M Pt 2: 46/F Pt 3: 46/M Pt 4: 33/M Pt 5: 40/F Pt 6: 49/M Pt: 56/M Not reported PASI90 at W6 None Heikkilä et al 24 4 Pt 1: 16/M Pt 2: 27/M Pt 3: 54M Pt 4: 29/M Not reported Not reported Not reported Case Report Kurokawa et al 25 1 45/M PASI: 43 BSA: >80 PASI: 5.6 at W13 None Trídico et al 26 1 55/M Not reported Infliximab effectiveness maintained over time (11 years) None Anti-IL17 Secukinumab Case Series Damiani et al 27 13 Age: 40 (range 28–52) M: 9 (69.2%) F: 4 (30.8%) PASI: not reported W16: PASI90/100: 5(38.5%)/4(30.8%) W52: PASI90/100: 5(38.5%)/5(38.5%) AEs: 5 (48.5%), with injection-site pain as the commonest (3, 60.0%) Weng et al 28 10 Age: 42.6 ± 11 M: 8 (80.0%) F: 2 (20.0%) PASI: 32.4 ± 5.7 BSA: 89.0 ± 7.1 W8: PASI75/90/100: 5(50.0%)/2(20.0%)/1(10.0%) W12: PASI75/90/100: 7(70.0%)/4(40.0%)1(10.0%) W16: PASI75/90/100: 7(70.0%)/4(40.0%)2(20.0%) W24: PASI75/90/100: 6(60.0%)/4(30.0%)1(10.0%) None …”

Section: Resultsmentioning

confidence: 98%

See 1 more Smart Citation

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review

Potestio¹,

Camela²,

Cacciapuoti³

et al. 2023

CCID

View full text Add to dashboard Cite

Erythrodermic psoriasis (EP) is a severe and rare variant of psoriasis (less than 3% of cases), characterized by generalized scaling and erythema affecting more than 90% of body surface area. Several systemic symptoms can be present in patients with EP such as lymphadenopathy, arthralgia, fever, fatigue, dehydration, serum electrolyte disturbances, and tachycardia making this condition a possible life-threatening disease, particularly if appropriate treatments are not performed. In this scenario, effective and safe therapies are required. Unfortunately, the rarity of EP makes head-to-head Phase III trials challenging, leading to the lack of established guidelines for its management. Globally, conventional systemic drugs such as cyclosporine, methotrexate, and retinoids often have contraindications linked to patients' comorbidities and have not shown a high profile of efficacy and safety. Recently, the development of biologic drugs including anti-tumor necrosis factor-α and anti-interleukin 12-23, 23, and 17 has revealed favorable results for the management of plaque psoriasis, making them also a possible therapeutic option for EP disease. However, their use in EP is still offlabel. The aim of our study was to review current literature on the use of biologic drugs for the treatment of EPs in order to offer a wide perspective on their possible application in EP management.

show abstract

Section: Resultsmentioning

confidence: 98%

“…80 As regards EP, few cases of this form of psoriasis successfully treated with infliximab have been described. [23][24][25][26] Among these, Takahashi et al reported the largest case series on seven patients successfully treated with infliximab. 23 All of the patients achieved PASI90 following the third infusion (week 6).…”

Section: Infliximabmentioning

confidence: 99%

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review

Potestio¹,

Camela²,

Cacciapuoti³

et al. 2023

CCID

View full text Add to dashboard Cite

show abstract

“…49,52 Infliximab Infliximab, a chimeric monoclonal antibody, is considered to be a first-line biologic for EP due to its rapid onset. 1,44,52,53,[55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70] In one multicenter study that included 24 patients, 52 one-third of the patients achieved PASI 75 at week 4 with infliximab treatment. But longterm efficacy is not so promising, as at the same study that only 48% of patients achieved PASI 75 at week 14, 52 and one case reported no further improvement after the sixth infusion of infliximab; the subject's condition was then controlled by administration of etanercept.…”

Section: Mycophenolate Mofetil (Mmf)mentioning

confidence: 99%

Updates on the Treatment of Erythrodermic Psoriasis

Lo¹,

Tsai

2021

PTT

View full text Add to dashboard Cite

Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy. Biologics have revolutionized the treatment of plaque-type psoriasis, and shown promise in EP. However, due to the lack of head-to-head studies and the rarity of EP, no high level evidence-based treatment guidelines for EP have been established, and the evidence of treatment of EP is limited to case reports or small case series. Here, we present a narrative review focusing on the up-to-date information for the treatment of EP.

show abstract

“…Management of psoriasis still faces severe challenges. Several topical treatments, including topical corticosteroids, calcineurin inhibitors, immunosuppressants, biological agents, etc, are recommended to alleviate the clinical symptom to varying degrees [6] . However, high costs and obvious side effects associated with the use of these medications limit their clinical application.…”

Section: Introductionmentioning

confidence: 99%

The effects of acupuncture for patients with psoriasis

Tao

et al. 2021

Medicine

View full text Add to dashboard Cite

Introduction:Psoriasis is a common chronic relapsing inflammatory skin disease, which may have considerable detrimental effects on the quality of life. Considering high costs and side effects associated with the use of conventional medications, acupuncture, as one of complementary and alternative nonpharmacological therapies, is commonly used in the management of psoriasis for reducing itching, repairing the skin lesions, etc. However, the effects of acupuncture in the management of psoriasis are still inconsistent, especially in psychosocial abnormality due to psoriasis. Therefore, we designed a randomized controlled trials (RCT) involving a placebo control to ensure participants’ blinding to investigate the effects of acupuncture for psoriasis in improving typical clinical symptoms and psychosocial abnormality.Methods:A singlecenter RCT was designed. 220 participants who meet the eligibility criteria will be randomly allocated into manual acupuncture group or sham acupuncture group in a 1:1 ratio. Participants will respectively receive 15 minutes manual acupuncture or sham acupuncture per session, 3 sessions per week, totally 12 weeks. Psoriasis Area and Severity Index scores, body surface area (BSA), Medical Outcomes Study 36-Item Short-Form Health Survey, Montgomery-Asberg Depression Rating Scale, and Depression, Anxiety, and Stress Scale-21 will be evaluated by blinded operators at baseline and 12 weeks. All analyses will be based on an intention-to-treat principle. The results will be published in an international peer-reviewed journal.Discussion:The results of this study are expected to clarify the effects of acupuncture on improving typical clinical symptoms and psychosocial abnormality of patients with psoriasis. It will contribute to clinical practice of acupuncture in the management of psoriasis.Trial registration:Chinese Clinical Trail Registry: ChiCTR2100045481. Registration date: April 17, 2021.

show abstract

Computed tomography imaging findings in erythrodermic psoriasis treated with infliximab: A case report

Cited by 5 publications

References 14 publications

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review

Updates on the Treatment of Erythrodermic Psoriasis

The effects of acupuncture for patients with psoriasis

Contact Info

Product

Resources

About